SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
SAKK 19/17:对PD-L1阳性、晚期非小细胞肺癌且体能状态评分为2的患者进行一线度伐利尤单抗治疗的安全性分析
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-020-02757-8
Mark, Michael; Froesch, Patrizia; Eboulet, Eric Innocents; Addeo, Alfredo; Pless, Miklos; Rothschild, Sacha I; Janthur, Wolf-Dieter; Burmeister, Henning; Friedlaender, Alex; Schneider, Martina; Metaxas, Yannis; Joerger, Markus; Wannesson, Luciano; Schwitter, Michael; Baudoux, Nathalie; Weindler, Susanne; Biaggi-Rudolf, Christine; Früh, Martin